Exogenous administration of FXa reduced viral copy numbers and protected a humanized hACE2 mouse model of COVID-19 from lethal infection, an effect that was attenuated by a direct but not an indirect FXa inhibitor and anticoagulant, which may have implications for clinical therapeutic responses. Here, F10 is linked to COVID-19.